Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $74.00 Price Target at Wells Fargo & Company

Posted by Brenda Bartman on Jul 13th, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) had its price target upped by Wells Fargo & Company from $57.00 to $74.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 16.65% from the stock’s current price.

KNSA has been the subject of several other research reports. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, June 29th. Citigroup raised their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Finally, Canaccord Genuity Group boosted their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $65.14.

Get Our Latest Research Report on KNSA

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $63.44 on Monday. The stock has a market capitalization of $4.88 billion, a PE ratio of 70.49 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 1 year low of $26.27 and a 1 year high of $67.53. The firm has a fifty day moving average price of $55.92 and a 200 day moving average price of $48.57.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 earnings per share. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International will post 1.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider directly owned 65,623 shares in the company, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 628,427 shares of company stock valued at $32,833,228 over the last three months. Company insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after purchasing an additional 49,802 shares in the last quarter. UBS Group AG boosted its position in shares of Kiniksa Pharmaceuticals International by 56.4% during the fourth quarter. UBS Group AG now owns 77,916 shares of the company’s stock worth $3,214,000 after purchasing an additional 28,099 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Kiniksa Pharmaceuticals International by 152.4% in the 4th quarter. Aberdeen Group plc now owns 400,598 shares of the company’s stock valued at $16,525,000 after buying an additional 241,876 shares during the period. SG Americas Securities LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after buying an additional 402,078 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Kiniksa Pharmaceuticals International by 27.3% in the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after buying an additional 178,366 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

(Get Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.